{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:36:31Z","timestamp":1768700191366,"version":"3.49.0"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T00:00:00Z","timestamp":1512518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Auburn University Research Initiative in Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2018,3,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Patients with cancer may use botanical dietary supplements (BDS) in an attempt to manage the side effects of chemotherapy, yet evidence about BDS use among patients with cancer is limited. The authors examined trends in BDS use among US adults according to cancer status and patient characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>A serial, cross\u2010sectional study was conducted using data from the National Health and Nutrition Examination Survey from 1999 through 2014 (n\u2009=\u200943,644). Self\u2010reported cancer diagnosis history and any BDS use in the preceding 30 days were determined. The prevalence of BDS use was calculated in each cycle for respondents with and without cancer, both overall and by patient characteristics. Simple linear regression models were applied to test for trends in BDS use at a 2\u2010sided <jats:italic>P<\/jats:italic> value\u2009&lt;\u2009.05. Multiple logistic regression models were performed to identify the patient factors associated with BDS use. The results were weighted to represent national estimates.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The prevalence of BDS use was greater among participants who had cancer compared with participants who did not have cancer, but trends remained stable during 1999 through 2014 for both groups. Trends in BDS use declined in patients with cancer who were older (<jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub>\u2009=\u2009.047), had a low annual family income (<jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub>\u2009=\u2009.028), and had a lower education level (<jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub>\u2009=\u2009.004). Among the respondents without cancer, trends in BDS use declined in those who were middle\u2010aged (<jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub>\u2009=\u2009.025), non\u2010Hispanic whites (<jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub>\u2009=\u2009.025), those with a lower education level (<jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub>\u2009=\u2009.011), and those who were not receiving prescription medication (<jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub>\u2009=\u2009.036). Patient age, sex, race\/ethnicity, income, education, and health conditions were associated with BDS use.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The overall use of BDS remained stable during 1999 through 2014 for US adults with and without cancer, but it varied by individual characteristics. <jats:bold><jats:italic>Cancer<\/jats:italic> 2018;124:1207\u201015.<\/jats:bold> \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.31183","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T09:55:15Z","timestamp":1512554115000},"page":"1207-1215","source":"Crossref","is-referenced-by-count":14,"title":["Trends in botanical dietary supplement use among US adults by cancer status: The National Health and Nutrition Examination Survey, 1999 to 2014"],"prefix":"10.1002","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2124-3282","authenticated-orcid":false,"given":"Chao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Health Outcomes Research and Policy Auburn University Harrison School of Pharmacy Auburn Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes Research and Policy Auburn University Harrison School of Pharmacy Auburn Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiahung","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes Research and Policy Auburn University Harrison School of Pharmacy Auburn Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela I.","family":"Calder\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Development Auburn University Harrison School of Pharmacy Auburn Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes Research and Policy Auburn University Harrison School of Pharmacy Auburn Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Deaths: Leading Causes for 2013","author":"Heron M","year":"2016"},{"key":"e_1_2_8_3_1","volume-title":"United States Cancer Statistics: 1999\u20102013 Incidence and Mortality Web\u2010based Report","author":"US Cancer Statistics Working Group","year":"2016"},{"key":"e_1_2_8_4_1","volume-title":"SEER Cancer Statistics Review, 1975\u20102014. Based on the November 2016 SEER data submission, posted to the SEER web site, April 2017","author":"Howlader N","year":"2017"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200611000-00006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0223"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.182"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7599.2003.tb00415.x"},{"key":"e_1_2_8_9_1","unstructured":"National Institute of Health Office of Dietary Supplements.Botanical Dietary Supplements. Available at:https:\/\/ods.od.nih.gov\/factsheets\/BotanicalBackground-HealthProfessional\/. Accessed November 9 2017."},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1081\/CNV-120005926","article-title":"Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials","volume":"20","author":"Andrew V","year":"2002","journal-title":"Cancer Invest"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-7-732"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601560"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.16.1247"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.16.1508.50958"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.06.007"},{"key":"e_1_2_8_16_1","first-page":"73431","article-title":"Pharmacokinetic interactions of herbs with cytochrome P450 and P\u2010glycoprotein [serial online]","volume":"2015","author":"Cho HJ","year":"2015","journal-title":"Evid Based Complement Altern Med"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00069"},{"key":"e_1_2_8_18_1","first-page":"763","article-title":"Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway","volume":"16","author":"Silje E","year":"2008","journal-title":"Support Care Cancer"},{"key":"e_1_2_8_19_1","unstructured":"National Center for Health Statistics.NHANES Response Rates and Population Totals. Available at:http:\/\/www.cdc.gov\/nchs\/nhanes\/response_rates_cps.htm. Accessed June 23 2017."},{"key":"e_1_2_8_20_1","unstructured":"National Cancer Institute.A to Z List of Cancer Drugs. Available at:https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs. Accessed June 22 2017."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.5.391"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.14403"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.8581"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/11593080-000000000-00000"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/2012.jama.11374"},{"key":"e_1_2_8_26_1","first-page":"66","volume-title":"Food Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective","author":"World Cancer Research Fund\/American Institute for Cancer Research (WCRF\/AICR)","year":"2007"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.024"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/872320"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0198-3"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2007.03-9040"},{"key":"e_1_2_8_31_1","first-page":"58","article-title":"Sex differences in motives for use of complementary and alternative medicine among cancer patients","volume":"10","author":"Hedderson MM","year":"2004","journal-title":"Altern Ther Health Med"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2008.0387"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2006.12.555"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2439"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8223(98)00068-6"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"djx145","DOI":"10.1093\/jnci\/djx145","article-title":"Use of alternative medicine for cancer and its impact on survival [serial online]","volume":"110","author":"Johnson SB","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13880200902991581"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2299"},{"key":"e_1_2_8_39_1","first-page":"2474","article-title":"Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen\u2010dependent human breast cancer (MCF\u20107) cells implanted in athymic mice","volume":"62","author":"Ju YH","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/0008-5472.879.65.3","article-title":"Low\u2010dose dietary phytoestrogen abrogates tamoxifen\u2010associated mammary tumor prevention","volume":"65","author":"Liu B","year":"2005","journal-title":"Cancer Res"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgn161"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.18.1569"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5905"},{"key":"e_1_2_8_44_1","unstructured":"US Food and Drug Administration (FDA).FDA News Release. FDA takes action against 14 companies for selling illegal cancer treatments. Available at:https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm554698.htm. Accessed November 3 2017."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:32:10Z","timestamp":1760293930000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,3,15]]}},"alternative-id":["10.1002\/cncr.31183"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31183","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,6]]}}}